HIMS241213C13000
- 20.50
- 0.000.00%
Hims & Hers Health Newsroom
Express News | "Weight-Loss Drug Craze Appears To Be Curbing U.S. Obesity Epidemic; Obesity Is Down In The U.S. For The First Time In A Decade. A New Study Suggests Weight-Loss Drugs May Explain Why" - Bloomberg News
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating
Truist Financial Gives a Hold Rating to Hims & Hers Health (HIMS)
Hims & Hers Health Insider Sold Shares Worth $2,653,129, According to a Recent SEC Filing
Josh Brown Unveils The 'Degen Dow,' A Basket Of 30 Retail Darlings Spanning All 'Major Degen Food Groups'
Unusual Options Activity: CRDO, HIMS and Others Attract Market Bets, CRDO V/OI Ratio Reaches 105.2
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Sell Rating, Maintains Target Price $18
Challenging Outlook for Hims & Hers Health Amid DTC Model Disruption and Profit Margin Concerns
'Eli Lilly to Sell Zepbound Through Telehealth Company Ro' - Barron's
Hims & Hers Health Unusual Options Activity
Hims & Hers Health, Inc. Falls 7% as Ro Says It Is Working With Eli Lilly to Streamline Access to Zepbound
Ro Partners With Eli Lilly to Enhance Obesity Treatment Access; Hims & Hers Health Shares Fall
Hims & Hers Health Options Spot-On: On December 10th, 88,818 Contracts Were Traded, With 573.71K Open Interest
CCORF Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Maintains Target Price $38
Hims & Hers Health: Buy Rating Backed by Promising Growth in GLP-1 Market and Strong Telehealth Positioning
10 Health Care Stocks Whale Activity In Today's Session
Hims & Hers Health Options Spot-On: On December 3rd, 64,567 Contracts Were Traded, With 531.51K Open Interest
Hims & Hers Named to Inc.'s 2024 Best in Business List in Health Products Category
Express News | 'ADA Advises Against Using Compounded GLP-1 RA Medications' - Medscape
Hims & Hers Health Options Spot-On: On December 2nd, 106.37K Contracts Were Traded, With 583.96K Open Interest